Metastatic gastric cancer treatment: Second line and beyond

doi:10.3748/wjg.v22.i11.3069

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 22, Issue 11

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (11066)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-1) series, Tables (1-2) series.

Item

Count

PDF

751

WORD

279

HTML

5025

Figures (1-1)

299

Tables (1-2)

254

Sum=6608

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

602

Download

916

Sum=1518

Publishing Process of This Article

Item

Count

Browse

1230

Download

1710

Sum=2940

Mar 21, 2016 (publication date) through Dec 22, 2024

Times Cited of This Article

Times Cited (28)

Journal Information of This Article

Publication Name

World Journal of Gastroenterology

ISSN

1007-9327

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Editorial

World J Gastroenterol. Mar 21, 2016; 22(11): 3069-3077
Published online Mar 21, 2016. doi: 10.3748/wjg.v22.i11.3069

Open in New Tab Full Size Figure Download Figure

Figure 1 Targets for monoclonal antibodies and tyrosine kinase inhibitors in advanced gastric cancer.

Citation: Ghosn M, Tabchi S, Kourie HR, Tehfe M. Metastatic gastric cancer treatment: Second line and beyond. World J Gastroenterol 2016; 22(11): 3069-3077
URL: https://www.wjgnet.com/1007-9327/full/v22/i11/3069.htm
DOI: https://dx.doi.org/10.3748/wjg.v22.i11.3069